secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193125-24-134238
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q1 revenue $44.9M (+21% YoY); organic revenue up 11%; reaffirms 2024 guidance
--------------------------------------------------------------------------------

- Total revenue $44.9M, +21% YoY; organic revenue (ex-Luminex) $37.3M, +11%.
- Gross profit margin 51% (down from 57%); adjusted gross margin 55% (down from 59%).
- Net loss $6.2M vs $6.8M loss; Adjusted EBITDA loss $0.7M vs $2.5M loss.
- Reaffirms 2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income for FY2024.
- Appointed William McCombe as CFO; opened new facility in Wuxi, China; received NMPA approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524134238/0001193125-24-134238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524134238/d814789d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer